These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23867140)

  • 1. The credibility of the FDA.
    Blankfield RP
    Eur J Prev Cardiol; 2013 Dec; 20(6):992-4. PubMed ID: 23867140
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The new FDA reality.
    Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):1-2. PubMed ID: 24444470
    [No Abstract]   [Full Text] [Related]  

  • 4. New FDA regulation to improve safety reporting in clinical trials.
    Sherman RB; Woodcock J; Norden J; Grandinetti C; Temple RJ
    N Engl J Med; 2011 Jul; 365(1):3-5. PubMed ID: 21651388
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA given new powers over data reporting to national clinical trials registry.
    Roehr B
    BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375
    [No Abstract]   [Full Text] [Related]  

  • 6. Percutaneous coronary intervention in perspective: drug-eluting stents as a model for regulatory review.
    Kandzari DE; Farb A; Boam AB
    Circ Cardiovasc Interv; 2009 Dec; 2(6):574-9. PubMed ID: 20031776
    [No Abstract]   [Full Text] [Related]  

  • 7. Through the looking glass: understanding non-inferiority.
    Schumi J; Wittes JT
    Trials; 2011 May; 12():106. PubMed ID: 21539749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Reporting: It Can Enter the 21st Century-If We Let It.
    Seltzer J; Bhattacharyya A
    Ther Innov Regul Sci; 2018 May; 52(3):354-361. PubMed ID: 29714542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacovigilance in Europe.
    Johnson CL; Hutchinson JA
    Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
    [No Abstract]   [Full Text] [Related]  

  • 11. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fundamental principles of clinical trials].
    Skarke C; Geisslinger G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):401-7. PubMed ID: 15830250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MedWatch, the new FDA adverse effects reporting system.
    Shader RI; Greenblatt DJ
    J Clin Psychopharmacol; 1993 Oct; 13(5):303-4. PubMed ID: 8227487
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of FDA safety-related drug label changes in 2010.
    Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA's MedWatch Program Monitors Drug Safety, But It Depends on Nurses to Report Adverse Events.
    Miller D
    ONS Connect; 2015 Sep; 30(3):49. PubMed ID: 26449124
    [No Abstract]   [Full Text] [Related]  

  • 16. Qualitative and quantitative scrutiny by regulatory process: is the truth subjective or objective?
    Dilsizian V; Narula J
    JACC Cardiovasc Imaging; 2009 Aug; 2(8):1037-8. PubMed ID: 19679295
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical-trial rules to improve access to results.
    Reardon S
    Nature; 2014 Nov; 515(7528):477. PubMed ID: 25428478
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulatory issues in pediatric psychopharmacology.
    Laughren TP
    J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Earlier identification of risks: cumulative probability analysis of time to safety alerts for therapeutic monoclonal antibodies.
    Stanulović V; Kadlecová P; Zelkó R; Kerpel-Fronius S
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):499-503. PubMed ID: 25997549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA: regulators or abdicators?
    Lancet; 2010 Oct; 376(9748):1196. PubMed ID: 20934577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.